MetaCap

Immunovant Inc. (IMVT)

NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

31.77-0.75 (-2.31%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMVT stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.56
52-week range
21.93 – 45.42
Day range
31.62 – 32.77
Volume / Avg
702.87K / 1.42M
Beta
—

52-week range

$21.93$45.42

IMVT stock today

Immunovant (IMVT) closed at $31.77 on Nov 20, down 2.31% (-$0.75), versus the S&P 500's 3.70% decline. Trading was light, with 702.87K shares changing hands, about 50% of the average daily volume. At this level, IMVT sits in the middle of its 52-week range of $21.93 to $45.42: 30.1% below the high, set on Aug 19, 2026 and 44.9% above the low.

IMVT is up 25.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 40.6%. Immunovant has posted a net loss over the last twelve months (EPS of -$2.56), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immunovant

Company profile

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Eric Venker M.D., Pharm.D.
Headquarters
Durham, NC
Employees
315
IPO year
2019

Financial highlights

Full financials

Immunovant reported a net loss of $505.6 million, compared with a loss of $413.8 million a year earlier. Diluted earnings per share came in at -$2.77.

Immunovant annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue—————
Growth—————
Net income$-505.61M$-413.84M$-259.34M$-210.96M$-156.73M
EPS (diluted)$-2.77$-2.73$-1.88$-1.71$-1.43

Analyst forecast

Forecast

Consensus (17 analysts)

buy

Avg. price target

$48.63+53.07%

  • Strong buy 2
  • Buy 11
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $33.00High $62.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.47 vs $-0.73
Surprise
+35.62%

IMVT news

All IMVT news

Immunovant peers

Health Care sector
IMVT peer companies
CompanyPrice% ChgMarket capCompare
IBRXImmunityBio Inc.6.02-8.37%$6.40Bvs IMVT
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs IMVT
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs IMVT
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs IMVT
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs IMVT
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs IMVT
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs IMVT
KRYSKrystal Biotech Inc.308.89-2.19%$9.15Bvs IMVT

Indexes, lists and sector

Immunovant stock FAQ

What is Immunovant's stock price today?

IMVT last traded at $31.77 as of Nov 20, 4:00 PM EST, down 2.31% on the day. Prices are delayed at least 15 minutes.

Who is Immunovant's CEO?

Dr. Eric Venker M.D., Pharm.D. is the chief executive officer of Immunovant Inc., which has about 315 employees.

What is the IMVT 52-week high?

The 52-week high for IMVT is $45.42 and the 52-week low is $21.93. The stock is currently 30.1% below its high.

Compare IMVT